← Back to Stories

Systematic review finds limited evidence for medicinal cannabis effectiveness in mental health conditions

2 hours ago2 articles from 2 sources

Consensus Summary

A large-scale systematic review by Australian and UK researchers published in *The Lancet Psychiatry* found no evidence that medicinal cannabis effectively treats anxiety, depression, PTSD, or other common mental health conditions despite its widespread prescription. The study analyzed 54 randomized controlled trials involving 2,477 participants and concluded that while cannabis may offer modest benefits for Tourette’s syndrome, insomnia, and autism traits—though with low-quality evidence—it lacks proven efficacy for mental health disorders. Prescriptions in Australia surged from fewer than 20,000 in 2020 to nearly 1 million in the last financial year, outpacing research into its safety and effectiveness. Critics like Sir Robin Murray argue the cannabis industry and clinics overstate benefits, while industry representatives dispute the findings, citing anecdotal patient success. One Australian case study in the SMH highlighted a man who quit cannabis after it exacerbated his mental health, illustrating the real-world variability in patient experiences.

✓ Verified by 2+ sources

Key details reported by multiple sources:

  • Medicinal cannabis prescriptions in Australia rose from fewer than 20,000 in 2020 to nearly 1 million in the last financial year
  • The University of Sydney’s systematic review included 54 randomised controlled trials with 2,477 participants, finding no evidence medicinal cannabis treats anxiety, depression, or PTSD
  • Researchers found some low-quality evidence that medicinal cannabis may reduce tic severity in Tourette’s syndrome, improve sleep for insomniacs, and help manage autism traits
  • Legal medicinal cannabis sales in Australia have tripled over four years, outpacing research into its safety and effectiveness
  • The review was published in *The Lancet Psychiatry* and led by researchers from the University of Sydney, Brisbane, Melbourne, and the University of Bath

Points of Difference

Details reported by only one source:

SMH
  • Daniel Yacoel, 33, reported quitting medicinal cannabis after realizing it worsened his anxiety and depression, noting he spent $300 weekly on scripts—equivalent to his rent—before stopping
  • The article mentions a federal government program for medicinal cannabis prescriptions, though the specific name is omitted
  • Dr Jack Wilson (University of Sydney) stated ‘a lot of people find their cannabis to be effective for their condition,’ acknowledging anecdotal success despite lack of robust evidence
  • The Cannabis Council spokesperson cited patient submissions to the Therapeutic Goods Administration (TGA) describing benefits, but did not directly address industry funding for trials
  • Three clinical trials for medicinal cannabis in mental health are underway in Australia, including studies for autism in children and CBD for anxiety in young people
GUARDIAN
  • Sir Robin Murray (King’s College London) called UK cannabis clinics ‘drug dealers for the middle class,’ criticizing industry claims and misinformation
  • The Advisory Council on the Misuse of Drugs in the UK is reviewing the 2018 legalization of cannabis-based products for ‘unintended consequences’
  • Mike Morgan-Giles (Cannabis Industry Council) disputed the review’s findings, stating ‘real-world evidence’ shows cannabis reduces anxiety and PTSD symptoms
  • The Guardian explicitly states no evidence exists for cannabis treating depression, while the SMH article did not address depression specifically in its conclusions
  • The review authors concluded ‘the routine use of cannabinoids for mental disorders is rarely justified’ due to scarcity of evidence

Contradictions

Conflicting information between sources:

  • The Guardian reports no evidence for cannabis treating depression, but the SMH article does not explicitly state whether depression was included in the review’s negative findings
  • The Cannabis Industry Council (quoted in the Guardian) claims ‘real-world evidence’ shows cannabis reduces anxiety and PTSD symptoms, contradicting the systematic review’s conclusion of ‘very little evidence’
  • The SMH article highlights Daniel Yacoel’s personal success quitting cannabis after it worsened his mental health, while the Guardian does not mention this case study
  • The Guardian attributes the review’s publication to *The Lancet Psychiatry*, but the SMH article does not name the journal, only stating it was published on Tuesday
  • The SMH notes the review did not distinguish between THC and CBD products, while the Guardian does not emphasize this limitation in its summary

Source Articles

SMH

The $300 a week medicine Daniel feels better without

Daniel Yacoel is one of hundreds of thousands of Australians prescribed medicinal cannabis for a mental health condition but there is little evidence it works....

17 March 2026
GUARDIAN

Cannabis is not an effective treatment for common mental health conditions, says review

International researchers find ‘very little evidence’ medical form of the drug can treat anxiety, anorexia and other disorders Cannabis is not an effective treatment for common mental health condition...

17 March 2026